TAVR for Aortic Valve Disease

Nanjing Medical University

Status: Enrolling

Conditions: Aortic Valve Disease

Treatments: Device: transcatheter heart valve

Study type: Observational

Funder types: Other

Identifiers

NCT05439863

NanjingValve Registry

Details and patient eligibility

About

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation
2. Patients undergo transcatheter aortic valve replacement

Exclusion criteria

patients refuse the clinical follow-up

Trial design

5,000 participants in 1 patient group

TAVR in aortic valve disease

Treatment:

Device: transcatheter heart valve